Close Menu

NEW YORK (GenomeWeb) – Antibiotic resistance diagnostics firm MicrobeDx today announced it has received up to $3.5 million in funding from CARB-X.

The award will be used by Los Angeles-based MicrobeDx to develop its diagnostic technology, which uses a compact desktop device to detect the presence of bacteria in clinical urine specimens, and to which antibiotics they are susceptible. Bacteria can be detected within 30 minutes, while complete antimicrobial susceptibility detection can be completed within three hours with the system, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.